EdiGene
Drug discovery startup EdiGene, which was spun out of the University of Tokyo, employs CRISPR-Cas9 gene editing techniques and has established a proprietary technology to miniaturize the Cas9 enzyme.
The company, which has sites in the USA and China, held a Series A funding round in 2017 which saw an 11.9% stake acquired by the med device arm of diversified tech firm Fujifilm in return for 470 million yen ($4 million).
In addition, the firms signed a joint research agreement aimed at discovering gene therapy drugs, combining Fujifilm's technology for liposomal formulations with EdiGene's genome editing platform.
Latest EdiGene News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze